Resverlogix grants Shenzhen Hepalink rights to RVX208 in some Asian territories; right of first refusal in US
Executive Summary
Resverlogix Corp. has licensed Shenzhen Hepalink Pharmaceutical Co. Ltd. rights to develop its lead cardiovascular compound RVX208 in China, Hong Kong, Taiwan, and Macau.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice